文献速递脑血管病

血浆脑源性tau与缺血性卒中后功能结局的相关性

Association of Plasma Brain-Derived Tau With Functional Outcome After Ischemic Stroke.
PubMed 文献 · Neurology · 2024-01-31

研究在SAHLSIS队列(454例,中位年龄58岁)和SAHLSIS2队列(364例,中位年龄68岁)中检测急性期血浆脑源性tau(BD-tau),分析其与3个月不良功能结局(改良Rankin量表评分>2)的关联。校正年龄、性别、采血天数和卒中严重程度后,两个队列中较高的急性BD-tau浓度均与不良结局的 odds 增加显著相关。

要点

  • SAHLSIS队列中,BD-tau每翻倍,不良功能结局的OR为2.9(95%CI 2.2-3.7),P=1×10-15。
  • SAHLSIS2队列中,BD-tau每翻倍,不良功能结局的OR为1.8(95%CI 1.5-2.2),P=7×10-9。
  • BD-tau是有前景的缺血性卒中结局血液生物标志物,但需在更大队列中进一步研究。

核心结论

  • BD-tau是有前景的缺血性卒中结局血液生物标志物,未来需在更大队列中进一步研究。

研究设计与样本

  • 在Sahlgrenska缺血性卒中学院研究(SAHLSIS)中纳入454例成人缺血性卒中病例和对照(均小于70岁),并在SAHLSIS2独立队列中纳入364例各年龄成人病例。
  • 采用新型选择性定量BD-tau的检测方法测定血浆tau,通过logistic回归分析其与3个月不良功能结局(改良Rankin量表评分>2)的关联。
  • 进行了按年龄、卒中严重程度、再通治疗和病因亚型等分层及敏感性分析。

主要发现

  • SAHLSIS队列中位年龄58岁,SAHLSIS2队列中位年龄68岁。
  • 校正年龄、性别、采血天数和卒中严重程度(NIH卒中量表评分)后,两个队列中较高的急性BD-tau浓度均与不良结局的 odds 增加显著相关:SAHLSIS队列BD-tau每翻倍OR为2.9(95%CI 2.2-3.7),P=1×10-15;SAHLSIS2队列BD-tau每翻倍OR为1.8(95%CI 1.5-2.2),P=7×10-9。
  • 该关联在不同分层和敏感性分析中保持一致。

关键数值与推荐

  • 不良功能结局定义为3个月改良Rankin量表评分>2。
  • SAHLSIS队列BD-tau每翻倍与不良结局关联的OR为2.9(95%CI 2.2-3.7),P=1×10-15。
  • SAHLSIS2队列BD-tau每翻倍与不良结局关联的OR为1.8(95%CI 1.5-2.2),P=7×10-9。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文指出未来需在更大队列中进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To investigate whether circulating acute-phase brain-derived tau (BD-tau) is associated with functional outcome after ischemic stroke. METHODS: Plasma tau was measured by a novel assay that selectively quantifies BD-tau in the Sahlgrenska Academy Study on Ischemic Stroke (SAHLSIS), which includes adult cases with ischemic stroke and controls younger than 70 years, and in an independent cohort of adult cases of all ages (SAHLSIS2). Associations with unfavorable 3-month functional outcome (modified Rankin scale score >2) were analyzed by logistic regression. Various stratified and sensitivity analyses were performed, for example, by age, stroke severity, recanalization therapy, and etiologic subtype. RESULTS: This study included 454 and 364 cases from the SAHLSIS and SAHLSIS2, with a median age of 58 and 68 years, respectively. Higher acute BD-tau concentrations were significantly associated with increased odds of unfavorable outcome after adjustment for age, sex, day of blood draw, and stroke severity (NIH stroke scale score) in both cohorts (OR per doubling of BD-tau: 2.9 [95% CI 2.2-3.7], P = 1 × 10-15 and 1.8 [1.5-2.2], P = 7 × 10-9, respectively). The association was consistent in the different stratified and sensitivity analyses. DISCUSSION: BD-tau is a promising blood-based biomarker of ischemic stroke outcomes, and future studies in larger cohorts are warranted.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Stanne TM, Gonzalez-Ortiz F, Brännmark C, et al. Association of Plasma Brain-Derived Tau With Functional Outcome After Ischemic Stroke. Neurology. 2024. PMID: 38545929. doi:10.1212/WNL.0000000000209129

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。